| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Protein kinase inhibitor 6 targets protein kinases. It inhibits the activity of specific protein kinases, which are enzymes that phosphorylate proteins and regulate various cellular processes. Its specific kinase targets and selectivity are not well characterized.
|
|---|---|
| ln Vitro |
In vitro, Protein kinase inhibitor 6 is used as a protein kinase inhibitor in research. Detailed IC50 values and selectivity data are not reported. It may be used to study kinase signaling pathways and their roles in cellular processes.
|
| ln Vivo |
In vivo, Protein kinase inhibitor 6 has potential applications in studying kinase-related diseases. Animal studies are needed to evaluate its in vivo efficacy and safety. No specific therapeutic applications have been reported.
|
| Enzyme Assay |
Cell-free assays for Protein kinase inhibitor 6 involve kinase activity assays. The compound is incubated with purified kinases and peptide substrates, and kinase activity is measured using radioactive or fluorescence-based detection. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Protein kinase inhibitor 6 use cells treated with the compound at concentrations of 0.1-100 µM for 1-24 hours. Kinase activity is measured in cell lysates. Phosphorylation of downstream targets is assessed by Western blot. Cell viability and proliferation are measured by MTT assay.
|
| Animal Protocol |
In vivo animal studies for Protein kinase inhibitor 6 have not been extensively reported. Based on its kinase inhibitory activity, animal models of cancer or other kinase-related diseases could be used. Animals would be administered the compound, and disease progression would be monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Protein kinase inhibitor 6 are not extensively characterized. As a small molecule (MW 147.17), it may have moderate bioavailability. Storage: typically at -20°C.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicity data for Protein kinase inhibitor 6 are limited. As a kinase inhibitor, it may have significant toxicity at high doses. It is for research use only and not approved for clinical use.
|
| Additional Infomation |
Protein kinase inhibitor 6 is a research compound used in kinase signaling studies. It is a protein kinase inhibitor. The compound is available from chemical suppliers. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C13H9FN2S
|
|---|---|
| Molecular Weight |
244.29
|
| Exact Mass |
244.047
|
| CAS # |
348-45-8
|
| PubChem CID |
2360905
|
| Appearance |
White to off-white solid powder
|
| Density |
1.384g/cm3
|
| Boiling Point |
372.2ºC at 760mmHg
|
| Flash Point |
178.9ºC
|
| Index of Refraction |
1.723
|
| LogP |
4.252
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
256
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KQKQLYWDIYNFJP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9FN2S/c14-9-5-7-10(8-6-9)15-13-16-11-3-1-2-4-12(11)17-13/h1-8H,(H,15,16)
|
| Chemical Name |
N-(4-fluorophenyl)-1,3-benzothiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | |
| 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | |
| 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
